Results 131 to 140 of about 39,929 (263)

Editorial: Langerhans Cells and How Skin Pathology Reshapes the Local Immune Environment

Frontiers in Immunology, 2019
Clare L. Bennett, Carrie A. Ambler
doaj   +1 more source

Case Report: Intra-articular injection of tocilizumab for arthritis treatment in chronic graft-vs.-host disease. [PDF]

Front Pediatr
Xie M, Liu Q, Yuan H, Chen Y, Zou X, Zhang Z, Zhong B, Zeng H, Zeng H.   +8 more
europepmc   +1 more source

The Role of Extracellular Vesicles (EVs) in Chronic Graft vs. Host Disease, and the Potential Function of Placental Cell-Derived EVs as a Therapeutic Tool. [PDF]

Int J Mol Sci, 2023
Zavaro M, Dangot A, Bar-Lev TH, Amit O, Avivi I, Ram R, Aharon A.   +6 more
europepmc   +1 more source

Catalytic Amyloids: Turning Fibrils Into Biocatalysts

Chemistry – A European Journal, EarlyView.
Amyloids, traditionally associated with diseases, have emerged as versatile catalytic scaffolds. From natural amyloid sequences to bioinspired and de novo designs, we highlight strategies to construct catalytic active sites and anchor enzymes onto fibrils, creating versatile nanomaterials with tunable activities. ABSTRACT Amyloids have been regarded as
Alessandra Esposito, Linda Leone, Flavia Nastri, Angela Lombardi   +3 more
wiley   +1 more source

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, EarlyView.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source

Influence of daytime of allogeneic stem cell transplantation on incidence of acute graft vs. host disease: a retrospective analytical cohort study. [PDF]

Bone Marrow Transplant
Wilcken H, Kaier K, Meyer T, Waterhouse M, Gräßel L, Duque-Afonso J, Marks R, Wäsch R, Finke J, Zeiser R, Maas-Bauer K, Wehr C.   +11 more
europepmc   +1 more source

Prevention of acute graft-vs.-host disease by targeting glycolysis and mTOR pathways in activated T cells. [PDF]

Exp Ther Med, 2022
Zhou RQ, Wang X, Ye YB, Lu B, Wang J, Guo ZW, Mo WJ, Yang Z, Srisuk P, Yan LP, Xu XJ.   +10 more
europepmc   +1 more source

Targeting MGAT4A‐Mediated N‐Glycosylation as a Therapeutic Strategy to Inhibit Glioblastoma Stem Cell Invasion

Exploration, EarlyView.
ABSTRACT Glioblastoma (GBM) is the most aggressive type of primary brain tumor, and its invasive properties contribute significantly to incomplete surgical resection and tumor recurrence. Despite extensive clinical efforts to mitigate GBM invasion, targeted therapies against GBM stem cells (GSCs), which drive invasion, remain incompletely understood ...
Rui Niu, Meichen Liu, Qingshan Yang, Jinlong Yin   +3 more
wiley   +1 more source

Mammalian target of rapamycin inhibitors as the treatment for steroid-refractory acute graft-vs.-host disease after allogeneic hematopoietic stem cell transplantation: A systematic review and individual patient data meta-analysis. [PDF]

Exp Ther Med
Guo Y, Li Z, Zhang Y, Pan Z, Sun J, Zhang Y, Chang S, Guo Z.   +7 more
europepmc   +1 more source

Case report: Sudden onset optic neuritis shortly after SARS-CoV-2 vaccination in an allogeneic hematopoietic stem cell transplant recipient with chronic graft-vs.-host disease. [PDF]

Front Med (Lausanne), 2023
Chu C, Jiang SK, Shao YC, Yeh SP.
europepmc   +1 more source